Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery
LONDON–(BUSINESS WIRE)–Plexāā, a MedTech startup behind the award-winning BLOOM43 medical device for breast surgery, has announced the close of a $4.5 million funding extension round. The strategic capital infusion will support the imminent U.S. launch of BLOOM43, while also laying the groundwork for future innovations. The funding also strengthens the company’s position ahead of their planned Series A fundraising round.
Complication rates in breast surgeries, which can include infection, skin necrosis and the need for additional surgeries, have been recorded as high as 30 percent. BLOOM43 is the world’s first fully wearable medical device designed to help patients prepare for breast cancer surgery and reconstruction by harnessing the power of Supraphysiological Preconditioning™. The new technique safely and intermittently thermally preconditions the skin causing the release of heat-shock proteins that cause vasodilation and increased blood flow to the area. This process has been shown to reduce wound healing complications in proof-of-concept clinical trials.
